News & Updates

Show Multimedia Only

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

17 Apr 2026

The first-in-class KRAS G12D–targeted protein degrader setidegrasib has demonstrated antitumour activity in patients with previously treated advanced non–small-cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma harbouring the KRAS G12D mutation, according to a phase I study.

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

17 Apr 2026

Gotistobart a chemo-free option for metastatic sqNSCLC

15 Apr 2026 by

Gotistobart monotherapy elicits an improved and durable antitumour response with a meaningful survival benefit relative to docetaxel in patients with metastatic squamous nonsmall cell lung cancer (sqNSCLC) who experience disease progression on or after anti-PD-(L)1 treatment, as shown by the results of the stage 1 PRESERVE-003 phase III trial.

Gotistobart a chemo-free option for metastatic sqNSCLC

15 Apr 2026

Novel combination therapies show potential in management of endocrine resistance in HR+/HER2- mBC

13 Apr 2026 by

Biomarker testing where appropriate and novel tailored combination therapies targeting multiple pathways simultaneously may address the high unmet need and optimize treatment outcomes in hormone receptor–positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (mBC) patients who develop resistance or have disease recurrence while on endocrine-based therapy (ET), said Professor Sherko Kümmel of the Interdisciplinary Breast Unit Clinics, Essen-Mitte, Germany, who spoke at the 14^th Asia-Pacific Breast Cancer Summit (APBCS 2026).

Novel combination therapies show potential in management of endocrine resistance in HR+/HER2- mBC

13 Apr 2026

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

13 Apr 2026 by

Perioperative treatment with enfortumab vedotin and pembrolizumab (EV plus pembro) significantly improves event-free survival (EFS), overall survival (OS), and pathological complete response (pCR) rates in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy, according to the KEYNOTE-905 trial presented at EAU26.

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

13 Apr 2026

Transurethral ultrasound ablation outperforms prostatectomy in early trial results

11 Apr 2026 by

The minimally invasive MRI-guided transurethral ultrasound ablation (TULSA) for prostate cancer is associated with better safety and periprocedural outcomes compared with robotic prostatectomy, according to the early results of the phase III CAPTAIN trial.

Transurethral ultrasound ablation outperforms prostatectomy in early trial results

11 Apr 2026

SG sees narrowing male-female gap in lung cancer incidence

10 Apr 2026 by

Singapore is seeing a shift in the incidence of lung cancer, with rising cases among women, including those who are younger and nonsmokers, according to local research.

SG sees narrowing male-female gap in lung cancer incidence

10 Apr 2026

CDI linked to adverse outcomes among hospitalized patients with cancer

09 Apr 2026

For hospitalized cancer patients, contracting Clostridioides difficile infection (CDI) contributes to a substantial increase in mortality and healthcare resource use, according to a cross-sectional study.

CDI linked to adverse outcomes among hospitalized patients with cancer

09 Apr 2026

Close relatives of Sjögren’s disease patients also at increased risk of cancer

06 Apr 2026

Patients with Sjögren’s disease (SjD) have a heightened risk of cancer, and this risk increase extends to their first-degree relatives, according to a study.

Close relatives of Sjögren’s disease patients also at increased risk of cancer

06 Apr 2026

Adagrasib shows promise in treatment of mutated solid tumours

05 Apr 2026

Treatment with the selective KRAS G12C inhibitor adagrasib significantly improves survival and yields high response rates in patients with KRAS G12C-mutant solid tumours, a study has shown.

Adagrasib shows promise in treatment of mutated solid tumours

05 Apr 2026

Which factors predict OS, nonoperative management in rectal adenocarcinoma?

04 Apr 2026

Receiving nonoperative management (NOM) and overall survival (OS) among patients with rectal adenocarcinoma are associated with several demographic factors and social determinants of health, according to a study.

Which factors predict OS, nonoperative management in rectal adenocarcinoma?

04 Apr 2026

News & Updates

Showing Oncology articles

Showing

Specialty:

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

Gotistobart a chemo-free option for metastatic sqNSCLC

Gotistobart a chemo-free option for metastatic sqNSCLC

Novel combination therapies show potential in management of endocrine resistance in HR+/HER2- mBC

Novel combination therapies show potential in management of endocrine resistance in HR+/HER2- mBC

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

Transurethral ultrasound ablation outperforms prostatectomy in early trial results

Transurethral ultrasound ablation outperforms prostatectomy in early trial results

SG sees narrowing male-female gap in lung cancer incidence

SG sees narrowing male-female gap in lung cancer incidence

CDI linked to adverse outcomes among hospitalized patients with cancer

CDI linked to adverse outcomes among hospitalized patients with cancer

Close relatives of Sjögren’s disease patients also at increased risk of cancer

Close relatives of Sjögren’s disease patients also at increased risk of cancer

Adagrasib shows promise in treatment of mutated solid tumours

Adagrasib shows promise in treatment of mutated solid tumours

Which factors predict OS, nonoperative management in rectal adenocarcinoma?

Which factors predict OS, nonoperative management in rectal adenocarcinoma?